A Phase 3 interventional study of ABT-450/r/ABT-267 and Ribavirin in Hepatitis C Virus, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-30.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing paritaprevir in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. paritaprevir · Hepatitis C.
Among the 29 studies testing paritaprevir in Hepatitis C, this one is the 10th largest by enrollment, is one of 2 that started in 2014, is one of 14 in phase 3, and was the 17th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 29 studies testing paritaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
paritaprevir: first FDA approval 2015 (TECHNIVIE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 171 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 99 across the 29 interventional studies. Of the 28 that completed or were terminated, 24 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 29 have an industry lead sponsor. The 6 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
90 studies in Hepatitis C by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 88 finished, 71 (81%) have results posted.
Among the 90 studies in Hepatitis C by AbbVie, this one is the 29th largest by enrollment of the 74 interventional ones that give a count, is one of 14 that started in 2014, is one of 46 in phase 3, and was the 27th registered.
AbbVie’s Hepatitis C studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing paritaprevir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 90 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, open-label, multicenter study, enrolling non-cirrhotic and cirrhotic subjects. The purpose of this study is to evaluate the efficacy and safety of ABT-450/r/ABT-267 co-administered with weight-based RBV for 12 or 16 weeks in adult chronic HCV genotype 2-infected treatment-naïve and interferon (IFN) treatment-experienced subjects with and without compensated cirrhosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based ribavirin (RBV; 400 to 1,000 mg/day, divided twice daily) for 12 weeks
Drug: ABT-450/r/ABT-267 · Drug: Ribavirin
ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based RBV (400 to 1,000 mg/day, divided twice daily) for 16 weeks
Drug: ABT-450/r/ABT-267 · Drug: Ribavirin
Drug pages: Paritaprevir · Ritonavir · Ombitasvir
Tablet; ABT-450 coformulated with ritonavir and ABT-267
Also known as: ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir also known as Norvir, VIEKIRAX Combination Tablets, VIEKIRA Combination Tablets, Technivie, Qurevo
Capsule
Percentage of Non-cirrhotic, Treatment-naive Participants in Each Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.
Time frame: 12 weeks after last dose of study drug
Percentage of Participants in Each Treatment Arm With On-treatment Virologic Failure During the Treatment Period
On-treatment virologic failure was defined as rebound (confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment, or confirmed increase from nadir in HCV RNA \[\> 1 log10 IU/mL above nadir\] at any time point during treatment) or failure to suppress HCV during treatment (all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment).
Time frame: 12 or 16 weeks (end of treatment period)
Percentage of Participants With Post-treatment Relapse
Relapse by post-treatment Week 12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug for a participant with HCV RNA \< LLOQ at the final treatment visit and who completed study treatment. Completion of treatment was defined as a study drug duration ≥ 77 days for the 12-week treatment arm or ≥ 105 days for the 16-week treatment arm.
Time frame: within 12 weeks after the last dose of study drug
Percentage of Participants With SVR12 Weeks Post-treatment for Each Treatment Arm Within Different Subpopulations
The percentage of participants with SVR12 in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; noncirrhotic participants who relapsed after prior IFN-based therapy (relapsers); noncirrhotic T-exp participants who were non-responders to prior IFN-based therapy; noncirrhotic T-exp participants who were intolerant to IFN-based therapy; participants with compensated cirrhosis.
Time frame: 12 weeks after last dose of study drug
Percentage of Participants in Each Treatment Arm With On-treatment Virologic Failure During the Treatment Period for Each Treatment Arm Within Different Subpopulations
The percentage of participants with on-treatment virologic failure in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; participants with compensated cirrhosis. On-treatment virologic failure was defined as rebound (confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment, or confirmed increase from nadir in HCV RNA \[\> 1 log10 IU/mL above nadir\] at any time point during treatment) or failure to suppress HCV during treatment (all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment).
Time frame: 12 or 16 weeks (end of treatment period)
Percentage of Participants With Post-treatment Relapse Within Different Subpopulations
The percentage of participants with relapse by post-treatment Week 12 in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; participants with compensated cirrhosis. Relapse by post-treatment Week 12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug for a participant with HCV RNA \< LLOQ at the final treatment visit and who completed study treatment. Completion of treatment was defined as a study drug duration ≥ 77 days for the 12-week treatment arm or ≥ 105 days for the 16-week treatment arm.
Time frame: within 12 weeks after the last dose of study drug
| Milestone | ABT-450/r/ABT-267 Plus RBV for 12 Weeks | ABT-450/r/ABT-267 Plus RBV for 16 Weeks |
|---|---|---|
| Started | 85 | 86 |
| Completed | 83 | 85 |
| Not completed | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.
| percentage of participants | ABT-450/r/ABT-267 Plus RBV for 12 Weeks | ABT-450/r/ABT-267 Plus RBV for 16 Weeks |
|---|---|---|
| Percentage of Non-cirrhotic, Treatment-naive Participants in Each Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment (SVR12) | 75.0 | 91.5 |
On-treatment virologic failure was defined as rebound (confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment, or confirmed increase from nadir in HCV RNA \[\> 1 log10 IU/mL above nadir\] at any time point during treatment) or failure to suppress HCV during treatment (all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment).
| percentage of participants | ABT-450/r/ABT-267 Plus RBV for 12 Weeks | ABT-450/r/ABT-267 Plus RBV for 16 Weeks |
|---|---|---|
| Overall | 8.3 | 8.5 |
| Rebound | 8.3 | 8.5 |
| Failure to suppress | 0 | 0 |
Relapse by post-treatment Week 12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug for a participant with HCV RNA \< LLOQ at the final treatment visit and who completed study treatment. Completion of treatment was defined as a study drug duration ≥ 77 days for the 12-week treatment arm or ≥ 105 days for the 16-week treatment arm.
| percentage of participants | ABT-450/r/ABT-267 Plus RBV for 12 Weeks | ABT-450/r/ABT-267 Plus RBV for 16 Weeks |
|---|---|---|
| Percentage of Participants With Post-treatment Relapse | 12.2 | 0 |
The percentage of participants with SVR12 in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; noncirrhotic participants who relapsed after prior IFN-based therapy (relapsers); noncirrhotic T-exp participants who were non-responders to prior IFN-based therapy; noncirrhotic T-exp participants who were intolerant to IFN-based therapy; participants with compensated cirrhosis.
| percentage of participants | ABT-450/r/ABT-267 Plus RBV for 12 Weeks | ABT-450/r/ABT-267 Plus RBV for 16 Weeks |
|---|---|---|
| All participants; n=85, 86 | 72.9 (62.7 to 81.2) | 81.4 (71.9 to 88.2) |
| Noncirrhotic participants; n=80, 80 | 72.5 (61.9 to 81.1) | 85.0 (75.6 to 91.2) |
| Noncirrhotic T-exp; n=32, 33 | 68.8 (51.4 to 82.0) | 75.8 (59.0 to 87.2) |
| Noncirrhotic T-exp Relapser; n=15, 16 | 80.0 (54.8 to 93.0) | 93.8 (71.7 to 98.9) |
| Noncirrhotic T-exp Nonresponder; n=5, 6 | 40.0 (11.8 to 76.9) | 50.0 (18.8 to 81.2) |
| Noncirrhotic T-exp IFN-intolerant; n=12, 11 | 66.7 (39.1 to 86.2) | 63.6 (35.4 to 84.8) |
| Cirrhotic Participants; n=5, 6 | 80.0 (37.6 to 96.4) | 33.3 (9.7 to 70.0) |
The percentage of participants with on-treatment virologic failure in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; participants with compensated cirrhosis. On-treatment virologic failure was defined as rebound (confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment, or confirmed increase from nadir in HCV RNA \[\> 1 log10 IU/mL above nadir\] at any time point during treatment) or failure to suppress HCV during treatment (all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment).
| percentage of participants | ABT-450/r/ABT-267 Plus RBV for 12 Weeks | ABT-450/r/ABT-267 Plus RBV for 16 Weeks |
|---|---|---|
| All Participants: Overall; n=85, 86 | 15.3 | 16.3 |
| All Participants: Rebound; n=85, 86 | 15.3 | 15.1 |
| All Participants: Failure to Suppress; n=85, 86 | 4.7 | 4.7 |
| Noncirrhotic: Overall; n=80, 80 | 15.0 | 13.8 |
| Noncirrhotic: Rebound; n=80, 80 | 15.0 | 12.5 |
| Noncirrhotic: Failure to Suppress; n=80, 80 | 3.8 | 3.8 |
| Noncirrhotic T-exp: Overall; n=32, 33 | 25.0 | 21.2 |
| Noncirrhotic T-exp: Rebound; n=32, 33 | 25.0 | 18.2 |
| Noncirrhotic T-exp: Failure to Suppress; n=32, 33 | 9.4 | 9.1 |
| Cirrhotic: Overall; n=5, 6 | 20.0 | 50.0 |
| Cirrhotic: Rebound; n=5, 6 | 20.0 | 50.0 |
| Cirrhotic: Failure to Suppress; n=5, 6 | 20.0 | 16.7 |
The percentage of participants with relapse by post-treatment Week 12 in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; participants with compensated cirrhosis. Relapse by post-treatment Week 12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug for a participant with HCV RNA \< LLOQ at the final treatment visit and who completed study treatment. Completion of treatment was defined as a study drug duration ≥ 77 days for the 12-week treatment arm or ≥ 105 days for the 16-week treatment arm.
| percentage of participants | ABT-450/r/ABT-267 Plus RBV for 12 Weeks | ABT-450/r/ABT-267 Plus RBV for 16 Weeks |
|---|---|---|
| All Participants; n=69, 70 | 10.1 | 0 |
| Noncirrhotic Participants; n=65, 68 | 10.8 | 0 |
| Noncirrhotic T-exp Participants; n=24, 25 | 8.3 | 0 |
| Cirrhotic Participants; n=4, 2 | 0 | 0 |
Collected over Non-serious adverse events collected from initiation of study drug through 30 days post-study drug dosing (12 weeks or 16 weeks, depending on arm assignment); serious adverse events collected from signing of Informed Consent up to Post-treatment Week 48.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABT-450/r/ABT-267 Plus RBV for 12 Weeks (Non-cirrhotic) | — | 0/80 (0%) | 52/80 (65%) |
| ABT-450/r/ABT-267 Plus RBV for 16 Weeks (Non-cirrhotic) | — | 3/80 (3.8%) | 53/80 (66.3%) |
| ABT-450/r/ABT-267 Plus RBV for 12 Weeks (Cirrhotic) | — | 0/5 (0%) | 3/5 (60%) |
| ABT-450/r/ABT-267 Plus RBV for 16 Weeks (Cirrhotic) | — | 0/6 (0%) | 4/6 (66.7%) |
| Event | ABT-450/r/ABT-267 Plus RBV for 12 Weeks (Non-cirrhotic) | ABT-450/r/ABT-267 Plus RBV for 16 Weeks (Non-cirrhotic) | ABT-450/r/ABT-267 Plus RBV for 12 Weeks (Cirrhotic) | ABT-450/r/ABT-267 Plus RBV for 16 Weeks (Cirrhotic) |
|---|---|---|---|---|
| GASTRITIS ALCOHOLICGastrointestinal disorders | 0/80 | 1/80 | 0/5 | 0/6 |
| BRONCHOPNEUMONIAInfections and infestations | 0/80 | 1/80 | 0/5 | 0/6 |
| INCISIONAL HERNIAInjury, poisoning and procedural complications | 0/80 | 1/80 | 0/5 | 0/6 |
| Event | ABT-450/r/ABT-267 Plus RBV for 12 Weeks (Non-cirrhotic) | ABT-450/r/ABT-267 Plus RBV for 16 Weeks (Non-cirrhotic) | ABT-450/r/ABT-267 Plus RBV for 12 Weeks (Cirrhotic) | ABT-450/r/ABT-267 Plus RBV for 16 Weeks (Cirrhotic) |
|---|---|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 16/80 | 20/80 | 0/5 | 1/6 |
| BLOOD BILIRUBIN INCREASEDInvestigations | 16/80 | 14/80 | 0/5 | 1/6 |
| HAEMOGLOBIN DECREASEDInvestigations | 6/80 | 4/80 | 1/5 | 0/6 |
| HEADACHENervous system disorders | 11/80 | 6/80 | 1/5 | 0/6 |
| HEAT ILLNESSInjury, poisoning and procedural complications | 0/80 | 0/80 | 1/5 | 0/6 |
| BLOOD URIC ACID INCREASEDInvestigations | 0/80 | 0/80 | 1/5 | 0/6 |
| PRURITUS GENERALISEDSkin and subcutaneous tissue disorders | 0/80 | 1/80 | 1/5 | 0/6 |
| MUSCULOSKELETAL STIFFNESSMusculoskeletal and connective tissue disorders | 0/80 | 0/80 | 1/5 | 0/6 |
| SOMNOLENCENervous system disorders | 0/80 | 0/80 | 1/5 | 0/6 |
| POLLAKIURIARenal and urinary disorders | 0/80 | 0/80 | 1/5 | 0/6 |
| Age, Customized(participants) | ABT-450/r/ABT-267 Plus RBV for 12 Weeks | ABT-450/r/ABT-267 Plus RBV for 16 Weeks | Total |
|---|---|---|---|
| < 65 years | 56 | 62 | 118 |
| ≥ 65 years | 29 | 24 | 53 |
| Sex: Female, Male(Participants) | ABT-450/r/ABT-267 Plus RBV for 12 Weeks | ABT-450/r/ABT-267 Plus RBV for 16 Weeks | Total |
|---|---|---|---|
| Female | 40 | 48 | 88 |
| Male | 45 | 38 | 83 |
No study locations are listed for this record.
The record gives a start of Jan 2014, a primary completion of Apr 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paritaprevir · Ritonavir · Ombitasvir · Ribavirin